

CANDICE O'HERN PERFETTO, M.D., F.A.C.O.G.
Reproductive Endocrinology and Infertility • Obstetrics and Gynecology

Center of Reproductive Medicine • www.infertilitytexas.com

7400 Fannin Street, Suite 1180, Houston, TX 77054 • P: 713.790.9900 • F: 713.790.9901

1015 Medical Center Blvd., Suite 2100, Webster, TX 77598 • P: 713.790.9900 • F: 713.790.9900

10905 Memorial Hermann Drive, Suite 207, Pearland, TX 77584 77054 • P: 281.332.0073 • F: 281.557.5837

PROFESSIONAL EXPERIENCE

Physician, Reproductive Endocrinology and Infertility 8/2014-Present
Center of Reproductive Medicine
Offices in Houston, Pearland and Webster, TX

EDUCATION AND TRAINING

Fellowship, Reproductive Endocrinology and Infertility 7/2011-6/2014
Postdoctoral Fellowship, Research Laboratory of Nihar Nayak, Ph.D., D.V.M. 7/2012-6/2014
"Ernest and Amelia Gallo Endowed Postdoctoral Fellow"
Stanford University Medical Center
Palo Alto, CA

Residency, Obstetrics and Gynecology (Ob/Gyn) 7/2007-6/2011
The George Washington University (GWU) Medical Center
Washington, DC

Medical Doctor 8/2003-6/2007
Georgetown University School of Medicine
Washington, DC

Bachelor of Science, Cellular and Developmental Biology 8/1999-6/2003
University of California, Santa Barbara
Santa Barbara, California
Highest Honors

BOARD CERTIFICATIONS

American Board of Ob/Gyn - Board Certified in General Ob/Gyn
Written Boards, Passed 2011.
Oral Boards, Passed 2012.

American Board of Ob/Gyn - Board Certified in Reproductive Endocrinology and Infertility
Written Boards, Passed 2014.
Oral Boards, Passed 2016.

MEDICAL LICENSE

Texas State Medical Board 2014-Present
California State Medical Board 2011-2014

PROFESSIONAL QUALIFICATIONS

ACLS and BLS Certified	2014-Current
Postdoctoral Fellow, Research Laboratory of Nihar Nayak, Ph.D., D.V.M.	2012-2014
Administrative Chief Resident	2010-2011
Curriculum Committee Member, The GWU Ob/Gyn Residency	2010-2011
Council for Resident Education in Ob/Gyn (CREOG) Leadership Workshop	2010
American College of Ob/Gyn (ACOG) Simulation Lab	2010
Teaching Resident, The GWU Ob/Gyn Residency	2009
Academic Track, The GWU Ob/Gyn Residency	2008-2011
"Residents as Teachers" Training and Certification	2007-2008

HONORS AND AWARDS

Top Doctor 2016, Houstonia Magazine	2016
Grant recipient, Ernest and Amelia Gallo Endowed Postdoctoral Fellow	2012-2014
Award recipient, Bass Society of Pediatric Scholars	2012-2014
Scholarship recipient, 60 th Annual Pacific Coast Reproductive Society	2012
The Resident Award, The George Washington University Ob/Gyn Residency	2011
Inductee, The Kane King Dodek Ob/Gyn Honor Society	2011
Superior CREOG Achievement Award, The GWU Ob/Gyn Residency	2008-2011
Research Elective, The George Washington University Ob/Gyn Residency	2009
The Intern of the Year, The George Washington University Ob/Gyn Residency	2008
University of California, Santa Barbara Dean's List	1999-2003

PROFESSIONAL MEMBERSHIPS

Texas Medical Association	2014-Present
Harris County Medical Society	2014-Present
Pacific Coast Reproductive Society	2011-Present
American Society of Reproductive Medicine	2010-Present
American College of Obstetricians and Gynecologists	2006-Present
Alumni, Pi Beta Phi Sorority	1999-Present

PUBLICATIONS

1. Dayal MB, Frankfurter D, **O'Hern C**, Peak D, Dubey A and Gindoff PR. The use of lead follicle diameter to initiate gonadotropin-releasing hormone antagonist does not affect in vitro fertilization clinical pregnancy, implantation, or live birth rates: a prospective randomized study. *Fertility and Sterility*. 2009;92(6):2047-2049.
2. Dayal MB, **O'Hern CB**. Ovotestis. eMedicine for WebMD. December 2009. Available at: <http://emedicine.medscape.com/article/256289-overview>.
3. **Perfetto CO**, Gordon JD. Myomectomy before IVF: Which fibroids need to be removed? *Middle East Fertility Society Journal*. 2011;16(1):42-44.
4. **Perfetto CO**, Dayal M and Dubuy A. Infertility: Diagnosis, management and treatment. In *Practice Guidelines for the treatment of patients with infertility*. Ed. Dubey A. Jaypee Brothers, India, 2011.
5. **Perfetto CO** and Westphal LM. Success and predicted pregnancy outcomes for oocyte and embryo donation. In *Principles of oocyte and embryo donation*. Ed. Sauer M. Springer, New York, 2013.
6. **Perfetto CO**, Horowitz GM, Bedaiwy MA, et al. Female Infertility and Fertility Preservation. In *Clinical Reproductive Medicine and Surgery: A Practical Guide*. Eds. Falcone T and Hurd WW. Springer, New York, 2013.

7. **Perfetto CO**, Murugappan G, Lathi RB. Time to next pregnancy in spontaneous pregnancies versus treatment cycles in patients with recurrent pregnancy loss. *Fertility Research and Practice*. 2015;1:5.
8. **Perfetto CO**, Fan X, Dhal S, Krieg SJ, Westphal LM, Lathi RB, Nayak NR. Expression of interleukin-22 in decidua of patients with early pregnancy and unexplained recurrent pregnancy loss. *Journal of Assisted Reproduction and Genetics*. 2015;32(6):977-984.
9. McQueen DB, **Perfetto CO**, Hazard FK, Lathi RB. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. *Fertility and Sterility*. 2015;104(4):927-931.
10. Murugappan G, Shahine L, **Perfetto CO**, Hickok LR, Lathi RB. Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss. Accepted for publication, *Human Reproduction*, 2016.

ABSTRACT PRESENTATIONS

1. **O'Hern CB**, Casey R, Keller J. Attitudes and knowledge about HPV in a college population after the FDA approval of an HPV vaccine. Poster presentation, District IV Annual ACOG Conference, 2010.
2. **Perfetto CO**, Milki AM. Diagnosis and management of bladder hematoma after oocyte retrieval. Poster presentation, Annual Meeting, PCRS, 2012.
3. **Perfetto CO**, Lathi RB. Incidence of chronic endometritis in recurrent pregnancy loss patients. Poster presentation, Annual Meeting, PCRS, 2012.
4. **Perfetto CO**, Lathi RB. Incidence of chronic endometritis and subsequent pregnancy outcomes in patients with recurrent pregnancy loss. Poster presentation, Annual Meeting, PCRS, 2013.
5. **Perfetto CO**, Lathi RB. Time to next pregnancy in spontaneous pregnancies versus treatment cycles in patients with recurrent pregnancy loss. Poster presentation, Annual Meeting, ASRM, 2013.
6. **Perfetto CO**, Fan X, Dahl S, Slayden O, Westphal LM, Nayak NR. Progesterone withdrawal upregulates IGFBP-1 in the primate endometrium: New insights on IGFBP-1 regulation and decidualization. Poster presentation, Annual Scientific Meeting, Society of Gynecologic Investigation, 2014.
7. McQueen D, **Perfetto CO**, Hazard FK, Lathi RB. Endometrial Inflammatory cells in women with recurrent pregnancy loss and chronic endometritis. Oral presentation, Annual Meeting, ASRM, 2014.
8. McQueen D, **Perfetto CO**, Hazard FK, Lathi RB. Miscarriage rates in women with recurrent pregnancy loss and untreated chronic endometritis. Oral presentation, Annual Meeting, ASRM, 2014.
9. Murugappan G, **Perfetto CO**, Lathi RB. Preimplantation genetic testing in patients with recurrent pregnancy loss. Oral presentation, Annual Meeting, ASRM, 2014.

ORAL PRESENTATIONS

1. Ovarian reserve testing. The George Washington University Ob/Gyn Grand Rounds, 2009.
2. Attitudes and knowledge about HPV in a college population after the FDA approval of an HPV vaccine. The Kane King Dodek Ob/Gyn Honor Society Annual Meeting, 2010.
3. Fertility preservation following a diagnosis of cancer. The George Washington University Ob/Gyn Visiting Professor, 2010.

RESEARCH GRANTS

1. Selective leukocyte trafficking in early pregnancy loss. "Ernest and Amelia Gallo Endowed Postdoctoral Fellow," Child Health Research Institute Trainee Support Grant. Stanford University. 7/2012-6/2014.

CLINICAL RESEARCH PROJECTS

1. 2014, AbbVie M12-671
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Elagolix in subjects with moderate to severe endometriosis-associated pain
2. 2014, Watson UL1208
Randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of Ulipristal Acetate for the intermittent treatment of abnormal uterine bleeding associated with leiomyomas
3. 2014, Beckman-Coulter
Multi-center clinical feasibility evaluation of the access AMH assay to measure AMH as an aid in the prediction of poor ovarian response to controlled ovarian stimulation
4. 2015, Ferring
Randomized, assessor-blind trial comparing Menopur (menotropins for injection) and recombinant FSH (follicle stimulating hormone) in a GnRH antagonist cycle with single-blastocyst transfer in a high responder subject population
5. 2015, Illumina
Prospective, multi-center, randomized controlled trial comparing pregnancy outcomes following selection and single embryo transfer (SET) based on preimplantation genetic screening (PGS) by next generation sequencing (NGS) versus standard morphological assessment
6. 2015, Merck MK8342B-061
Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK- 8342B (etonogestrel + 17 β -estradiol) vaginal ring in healthy women 18 years of age and older, at risk for pregnancy
7. 2015, AbbVie M12-821
Extension study to evaluate the long-term safety and efficacy of Elagolix in subjects with moderate to severe endometriosis-associated pain
8. 2015, Merck MK8342B-060
Phase 3 randomized, double-blind, placebo-controlled, trial to study the efficacy and safety of MK- 8342B (ENG-E2 vaginal ring) in women with moderate to severe primary dysmenorrhea
9. 2015, AbbVie M12-815
Phase 3 study to evaluate the safety and efficacy of Elagolix in pre-menopausal women with heavy menstrual bleeding associated with uterine fibroids